Skip to main content

Clinical Trials Using Tislelizumab

Review the clinical trials studying tislelizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Status: Active
Location: 10 locations
A Study of BG-C477 in Participants With Advanced Solid Tumors
Status: Active
Location: 7 locations
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Status: Active
Location: 5 locations
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Status: Active
Location: 5 locations
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 6 locations
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: 6 locations
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: 2 locations
Tislelizumab Before and After Radiation Therapy for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
Fruquintinib and Tislelizumab for the Treatment of Colorectal Cancer in Patients with Minimal Residual Disease after Chemotherapy Treatment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tislelizumab and SX-682 before Surgery for the Treatment of Newly Diagnosed and Resectable Pancreatic Cancer
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Tislelizumab and Pamiparib in Combination with Concurrent Chemotherapy and Radiation Therapy for the Treatment of Patients with Previously Treated Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Tislelizumab for the Treatment of Patients with Mismatch Repair Deficient Metastatic Colorectal Cancer or Stage II or III Rectal Cancer
Status: Approved
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Status: Active
Location: See ClinicalTrials.gov